Advertisement

Carcinogenic Effects of Immunosuppressive Drugs in Man

  • D. Schmähl
  • B. Bunk
Conference paper

Abstract

There is hardly any other field in chemical carcinogenesis in which such good agreement between experimental and clinical results has been reached as in carcinogenesis induced by antineoplastic agents. As early as 1967, the carcinogenic effects of the two alkylating drugs cyclophosphamide and triazichone in rats were reported (Schmähl 1967). The results were systematically supported in later experiments and extended to other antineoplastic compounds (Schmähl and Osswald 1970). The investigations revealed that predominantly those antineoplastic drugs which have an alkylating mechanism of action had to be classified as potential carcinogens, whereas antimetabolites and antimitotics exerted practically no carcinogenic effects. The doses required to induce cancer in rats and mice corresponded to doses administered to patients on a mg/kg basis. The findings obtained in 1970 were later on confirmed in numerous investigations carried out in other laboratories (see review in Schmähl and Kaldor 1986). Experiments on the mechanism of the carcinogenic action of alkylating agents yielded the clear result that this type of carcinogenesis is not linked to the immunosuppressive porperties of alkylating agents, but is due to direct interaction between the alkylating agent and DNA.

Keywords

Transplant Recipient Latent Period Alkylating Agent Induction Time Polycythemia Vera 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brock N, Schneider B, Stekar J, Pohl J (1989) Experimental investigations into the carcinogenic effect of antitumor and immunosuppressive agents. J Cancer Res Clin Oncol 115:309–328PubMedCrossRefGoogle Scholar
  2. Chambers SK, Chopyk RL, Chambers JT, Schwartz PE, Duffy TP (1989) Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer 64:2459–2461PubMedCrossRefGoogle Scholar
  3. Coleman MP, Bell CMJ, Fraser P (1987) Second primary malignancy after Hodgkin’s disease, ovarian cancer and cancer of the testis: a population based cohort study. Br J Cancer 56:349–355PubMedCrossRefGoogle Scholar
  4. Greene MH, Harris EL, Gerschenson DM, Malkasian GD et al. (1986) Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Int Med 105:360–367PubMedGoogle Scholar
  5. Kempf SR, Ivankovic S (1986) Chemotherapy induced malignancies in rats after treatment with cisplatin as single agent and in combination: preliminary results. Oncology 43:187–191PubMedCrossRefGoogle Scholar
  6. Penn I (1988) Immunosuppression and neoplasia: cancers after cyclosporine therapy. Transplant Proc 20:276–279PubMedGoogle Scholar
  7. Petru E, Schmähl D (1990) Chemotherapy induced second primary neoplasms; clinical aspects. Neoplasma, in pressGoogle Scholar
  8. Schmähl D (1967) Karzinogene Wirkung von Cyclophosphamid und Triazichon bei Ratten. Dtsch Med Wochenschr 92:1150–1152CrossRefGoogle Scholar
  9. Schmähl D (1977) Carcinogenic action of anticancer drugs with special reference to immunosuppression. Cancer 40:1927–1929PubMedCrossRefGoogle Scholar
  10. Schmähl D, Kaldor JM (ed) (1986) Carcinogenicity of alkylating cytostatic drugs. IARC Sci Publ 78. IARC LyonsGoogle Scholar
  11. Schmähl D, Osswald H (1970) Experimentelle Untersuchungen über carcinogene Wirkungen von Krebschemotherapeutika und Immunsuppressiva. Arzneimittelforschung (Drug Res) 20:1461–1467Google Scholar
  12. Schmähl D, Petru E (1986) Zweittumoren nach cytostatischer Therapie mit Alkylantien beim Menschen; toxikologische Gesichtspunkte. Dtsch Med Wochenschr 111:833–836PubMedCrossRefGoogle Scholar
  13. Tucker MA, Meadows AT, Boice JR, Stovall M et al. (1987) Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 78:459–464PubMedGoogle Scholar
  14. Vathaire F, Francois P, Hill C, Schweisguth O et al. (1989a) Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 59:792–796PubMedCrossRefGoogle Scholar
  15. Vathaire F, Schweisguth O, Rodary C, Francois P et al. (1989b) Long term risk of second malignant neoplasms after cancer in childhood. Br J Cancer 59:448–452PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • D. Schmähl
  • B. Bunk

There are no affiliations available

Personalised recommendations